PMV Pharmaceuticals公布Pynnacle 2期试验中Rezatapopt单一疗法治疗携带TP53 Y220C突变多种实体瘤的积极中期数据

美股速递
Sep 10

PMV Pharmaceuticals公布了其药物Rezatapopt单一疗法在Pynnacle 2期试验中的积极中期数据,该试验针对携带TP53 Y220C突变的多种实体瘤患者。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10